South Africa And Europe Poct Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2023 –2030 |
 Marktgröße (Basisjahr) | USD 8,565.13 Million |
 Marktgröße (Prognosejahr) | USD 17,289.45 Million |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Point-of-Care-Testing (POCT)-Markt in Südafrika und Europa, nach Produkttyp (Glukoseüberwachungsprodukte, Infektionskrankheitstestprodukte, kardiometabolische Überwachungsprodukte, Schwangerschafts- und Fruchtbarkeitstestprodukte, Hämatologietestprodukte, Gerinnungsüberwachungsprodukte, Drogentestprodukte (DOA), Urinanalysetestprodukte, Cholesterintestprodukte, Tumor-/Krebsmarkertestprodukte, Produkte für Tests auf okkultes Stuhlbild und andere), Anwendung (Blutzucker, Herzüberwachung, Hämatologiegerinnung, Vollblutanalyse, Vitalzeichenüberwachung, nichtinvasive Spo2-Überwachung, nichtinvasive Pco2-Überwachung, Bluttransfusion und andere), Verschreibungsmodus (Verschreibungsbasierte Tests und rezeptfreie Tests), Plattform (Lateral Flow Assays/ Immunchromatographietests, Dipsticks, Molekulardiagnostik , Immunoassays, Mikrofluidik , klinisch-chemische Assays, Hämatologie und andere), Endbenutzer (Kliniken, häusliche Pflege, Krankenhäuser, Labore, ambulante Operationszentren und andere), Vertriebskanäle (Direktausschreibung, Einzelhandelsverkäufe, Online-Verkäufe und andere) – Branchentrends und Prognosen bis 2030.
Marktanalyse und Einblicke für Point-of-Care-Tests (POCT) in Südafrika und Europa
Einer der Hauptfaktoren, die das Wachstum des südafrikanischen und europäischen Marktes für Point-of-Care-Tests (POCT) vorantreiben, ist die zunehmende Verbreitung verschiedener chronischer und infektiöser Krankheiten. Das steigende Bewusstsein für Point-of-Care-Testprodukte führt zu einer Marktexpansion. Der Markt wird auch durch den intensiven Wettbewerb zwischen den Marktteilnehmern beeinflusst. Die mit POCT-Produkten verbundenen hohen Kosten könnten jedoch im Prognosezeitraum ein hemmender Faktor für den Markt sein.
Andererseits bieten das steigende Bewusstsein und die staatliche Förderung Chancen für das Wachstum des Marktes. Die fehlende Übereinstimmung mit den Testergebnissen aus Laboren kann jedoch den Point-of-Care-Testing-Markt (POCT) in Südafrika und Europa vor Herausforderungen stellen.
Der südafrikanische und europäische Markt für Point-of-Care-Tests (POCT) wird im Prognosezeitraum von 2023 bis 2030 voraussichtlich ein Marktwachstum verzeichnen. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum von 2023 bis 2030 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 9,3 % wächst und von 8.565,13 Millionen USD im Jahr 2022 auf 17.289,45 Millionen USD im Jahr 2030 ansteigen dürfte.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2023 bis 2030 |
|
Basisjahr |
2022 |
|
Historische Jahre |
2021 Anpassbar (2015-2020) |
|
Quantitative Einheiten |
Umsatz in Mio. USD |
|
Abgedeckte Segmente |
Produkttyp (Glukoseüberwachungsprodukte, Produkte zur Infektionskrankheitsprüfung, Produkte zur kardiometabolischen Überwachung, Produkte zur Schwangerschafts- und Fruchtbarkeitsprüfung, Hämatologie-Testprodukte, Gerinnungsüberwachungsprodukte, Drogentestprodukte (DOA), Urinanalyse-Testprodukte, Cholesterin-Testprodukte, Produkte zur Tumor-/Krebsmarkerprüfung, Produkte zur Prüfung auf okkulte Substanzen im Stuhl und andere), Anwendung (Blutzucker, Herzüberwachung, Hämatologie-Koagulation, Vollblutanalyse, Überwachung der Vitalfunktionen, nichtinvasive Spo2-Überwachung, nichtinvasive Pco2-Überwachung, Bluttransfusion und andere), Verschreibungsmodus (Verschreibungspflichtige Tests und rezeptfreie Tests), Plattform (Lateral-Flow-Assays/Immunchromatographie-Tests, Teststreifen, Molekulardiagnostik, Immunoassays, Mikrofluidik, klinisch-chemische Tests, Hämatologie und andere), Endbenutzer (Kliniken, häusliche Pflege, Krankenhäuser, Labore, ambulante chirurgische Zentren und andere), Vertriebskanal (Direkt Ausschreibungen, Einzelhandelsumsätze, Online-Verkäufe und andere) |
|
Abgedeckte Länder |
Südafrika, Deutschland, Frankreich, Großbritannien, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei, Belgien und Rest von Europa. |
|
Abgedeckte Marktteilnehmer |
F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Werfen, Sysmex Europe SE., Danaher, Quidel Corporation, LumiraDx, BD, Abbott, Nova Biomedical, Abaxis, Trividia Health, Inc., Sekisui Diagnostics, Thermo Fisher Scientific Inc., EKF Diagnostics, Trinity Biotech, Chembio Diagnostics, Inc., PTS Diagnostics, binx health, inc. und QuantuMDx Group Ltd. unter anderem. |
Marktdefinition
Der Point-of-Care-Testing-Markt (POCT) bezeichnet den Markt für diagnostische Tests, die am oder in der Nähe des Patienten durchgeführt werden und sofortige Ergebnisse für die klinische Entscheidungsfindung liefern. Bei POCT werden medizinische Tests außerhalb der traditionellen Laborumgebung durchgeführt, typischerweise in Einrichtungen wie Krankenhäusern, Kliniken, ambulanten Pflegezentren, Arztpraxen und sogar bei Patienten zu Hause. POCT ist darauf ausgelegt, einen schnellen und bequemen Zugriff auf diagnostische Informationen zu ermöglichen, sodass medizinisches Fachpersonal sofortige Behandlungsentscheidungen treffen, den Zustand der Patienten überwachen und die allgemeine Patientenversorgung verbessern kann. Die im Rahmen von POCT durchgeführten Tests decken ein breites Spektrum medizinischer Disziplinen ab, darunter Infektionskrankheiten, Herz-Kreislauf-Gesundheit, Diabetesbehandlung, Schwangerschaft und Fruchtbarkeit, Onkologie und Hämatologie.
Marktdynamik für Point-of-Care-Tests (POCT)
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:
Treiber
- Zunehmende Verbreitung von Infektionskrankheiten und chronischen Krankheiten
Die Prävalenz von Infektions- und chronischen Krankheiten wie Krebs, Diabetes und Herz-Kreislauf-Erkrankungen nimmt in ganz Europa rapide zu. Laut der Weltgesundheitsorganisation (WHO) betrug der Anteil chronischer Krankheiten etwa 60 % der Todesfälle. In Europa ist der Hauptgrund für die steigende Zahl chronischer Krankheiten die kontinuierliche Zunahme der geriatrischen Bevölkerung. Diese steigenden Krankheitsraten sind direkt proportional zum Wachstum von POCT, da diese bei der Diagnose fast aller Krankheiten eingesetzt werden.
Somit wird ein deutlicher Anstieg der Prävalenz chronischer Krankheiten ein wichtiger Wachstumstreiber für den Markt sein, da POCT-Geräte die Krankheit wirksam behandeln und bei Bedarf für mehr Komfort und eine bessere Behandlung zur Überwachung sorgen können.
- Verbesserte Diagnosesuchrate
Verbesserungen im Gesundheitsbereich und regelmäßige Schulungen für das mit den Tests betraute Fachpersonal haben zu höheren Diagnoseraten in der Region beigetragen. Dazu gehört auch eine Zunahme der erfolgreichen Diagnosen chronischer Krankheiten wie Krebs, Herz-Kreislauf-Erkrankungen, Typ-2-Diabetes und anderer.
Es wurde eine Methodik eingeführt, die Management, Zeitaufwand des Fachpersonals für die Diagnose und Bewertungsaktivitäten zur Unterstützung des POCT-Prozesses abdeckt. Dies trägt dazu bei, die Genauigkeit der Informationen zu verbessern und bessere Entscheidungen in Bezug auf die Diagnose zu treffen. Die Bemühungen von Gesundheits- und IT-Fachleuten, eine verbesserte Ausbildung des Gesundheitspersonals, Änderungen im System der Patientenversorgung und eine verbesserte Diagnosesuchrate in der Region führen also zu Marktwachstum.
- Nachfrage nach tragbaren Geräten zur Glukoseüberwachung
Da Diabetes heutzutage immer häufiger vorkommt, sind Blutzuckermessgeräte für die Patienten überlebenswichtig, da sie bei der Bestimmung des Blutzuckerspiegels helfen. Durch die einfache Einhaltung der Vorschriften bietet POCT den Patienten Komfort, da sie ihren Gesundheitszustand durch die Überprüfung mit dem Gerät erkennen und so unerwünschte Gesundheitsprobleme vermeiden können.
Daher wird die Einführung neuer tragbarer Geräte zur Glukoseüberwachung das Marktwachstum vorantreiben.
Gelegenheiten
-
Strategische Initiativen der Marktteilnehmer
Die zunehmende Verbreitung chronischer und infektiöser Krankheiten in Europa erfordert neue und fortschrittliche POCT-Kits und -Lösungen mit verbesserter Wirksamkeit und verkürzten Zykluszeiten aufgrund der Zunahme der geriatrischen Bevölkerung und auch zur Verbesserung des Gesundheitsmanagements und der Diagnostik für eine qualitativ hochwertige Leistung. Wichtige Marktführer sind bestrebt, die Anforderungen der Gesundheitsfachkräfte vollständig zu erfüllen und investieren ihre Zeit in die Forschung, um bessere Produkte, Kits und Reagenzien herzustellen.
Zum Beispiel,
-
Im Mai 2020 übernahm Roche Stratos Genomics, ein Startup-Unternehmen in der Anfangsphase der Sequenzierungstechnologiebranche, um die Entwicklung seines Nanoporen-Sequenzers voranzutreiben, der elektronische und biologische Komponenten kombiniert, um DNA für schnelle, anpassbare und kostengünstige klinische Diagnosetests zu sequenzieren.
Daher stellen diese strategischen Initiativen der Marktakteure eine Chance dar, die ihnen hilft, das Marktwachstum voranzutreiben.
-
Steigendes Bewusstsein und staatliche Förderung
Die Regierung, Verbände und wichtige Marktteilnehmer sind daran beteiligt, das Bewusstsein der Gesellschaft in Entwicklungsländern zu schärfen. Diese Initiativen der Akteure und der Regierung helfen den Nutzern, die für einkommensschwache Länder und Entwicklungsländer getroffenen Maßnahmen zu nutzen und sie auf Krankheiten aufmerksam zu machen, die bei früherer Diagnose vermeidbar sind. Das Wachstum von POCT in Krankenhäusern und Notaufnahmen wird bereits durch Regierungsinitiativen und die Prävalenz zeitkritischer medizinischer Erkrankungen stark gefördert.
Einschränkungen/Herausforderungen
- Mangelnde Genauigkeit bei POCT-Produkten
Die Genauigkeit eines POCT hängt von der Qualität des Tests selbst ab. Einige POCT-Geräte weisen im Vergleich zu Labortests möglicherweise eine geringere Sensitivität oder Spezifität auf. Um genaue Ergebnisse zu gewährleisten, ist es wichtig, qualitativ hochwertige, validierte POCT-Geräte zu verwenden. Einige Erkrankungen oder bestimmte Tests können inhärente Einschränkungen hinsichtlich der Genauigkeit aufweisen, unabhängig davon, ob sie in einem Labor oder am Behandlungsort durchgeführt werden. Es ist wichtig, sich der Einschränkungen und potenziellen Fehlerquellen bewusst zu sein, die mit bestimmten POCT-Geräten oder -Tests verbunden sind. Im Bereich POCT sind präanalytische Fehler ziemlich häufig. Infolgedessen begrenzen diese Umstände die Entwicklung neuer Produkte, behindern die Marktexpansion, führen zu Produktrückrufen und werden zur dauerhaften Rücknahme durchgeführt.
- Hohe Kosten des POCT- Produkts
Die hohen Kosten von POCT-Produkten, einschließlich Testgeräten, Kartuschen und Verbrauchsmaterial, können die Einführung und Implementierung von POCT-Programmen für Gesundheitsdienstleister, insbesondere kleinere Kliniken und Einrichtungen, finanziell schwierig machen. Die Anfangsinvestitionen für den Kauf der erforderlichen Ausrüstung und die Aufrechterhaltung der Versorgung mit Verbrauchsmaterialien können ein erhebliches Hindernis darstellen. Die hohen Kosten von POCT-Produkten können sich auch indirekt auf die Patienten auswirken. Wenn die Kosten für POCT auf die Patienten abgewälzt werden, kann dies dazu führen, dass die Tests für einige Personen unerschwinglich werden, insbesondere für diejenigen ohne Versicherungsschutz oder mit hohen Selbstbeteiligungen. Dies kann die Einführung und Nutzung von POCT behindern, da sich Patienten möglicherweise für alternative Testmethoden entscheiden oder ganz auf Tests verzichten.
Jüngste Entwicklungen
- Im April 2022 stellte Sysmex Europe SE die Point-of-Care-Testgeräte auf dem 24. IFCC-EFLM-Kongress für Klinische Chemie und Labormedizin in München vor. Die Produkteinführung führte zu verstärkten Partnerschaften mit Marktteilnehmern zur Nutzung und Verteilung von POCT-Geräten sowie zur Aufnahme eines neuen Produkts in das Produktportfolio, was zu einer Umsatzsteigerung führte.
- Im April 2021 gab Danaher bekannt, dass renommierte Wissenschaftler einem neuen wissenschaftlichen Beirat beitreten werden, um die Entwicklung neuer Technologien zu unterstützen und einzigartige Perspektiven auf schnell aufkommende Wissenschafts- und Technologietrends einzubringen, die Danaher beeinflussen. Dies half dem Unternehmen bei der Diversifizierung seines Segmentportfolios.
Marktumfang für Point-of-Care-Tests (POCT) in Südafrika und Europa
Der südafrikanische und europäische Markt für Point-of-Care-Tests (POCT) ist in sechs wichtige Segmente unterteilt, basierend auf Produkttyp, Anwendung, Verschreibungsmodus, Plattform, Endbenutzer und Vertriebskanal. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse schwacher Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, um strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.
Produkttyp
- Produkte zur Glukoseüberwachung
- Produkte zur Untersuchung von Infektionskrankheiten
- Produkte zur kardiometabolischen Überwachung
- Produkte für Schwangerschafts- und Fruchtbarkeitstests
- Produkte für Hämatologietests
- Produkte zur Gerinnungsüberwachung
- Produkte für den Drogenmissbrauchstest
- Produkte zur Urinanalyse
- Produkte zur Cholesterinuntersuchung
- Produkte zur Tumor-/Krebsmarker-Testung
- Produkte für Tests auf verborgene Substanzen im Stuhl
- Sonstiges
Auf der Grundlage des Produkttyps ist der südafrikanische und europäische Markt für Point-of-Care-Tests (POCT) in Produkte zur Glukoseüberwachung, Produkte zur Infektionskrankheitstestung, Produkte zur kardiometabolischen Überwachung, Produkte zur Schwangerschafts- und Fruchtbarkeitstestung, Produkte zur Hämatologietestung, Produkte zur Gerinnungsüberwachung, Produkte zur Drogenbestimmung (DOA), Produkte zur Urinanalyse, Produkte zur Cholesterinuntersuchung, Produkte zur Tumor-/Krebsmarkeruntersuchung, Produkte zur Untersuchung auf verborgene Stuhlproben und andere unterteilt.
Anwendung
- Blutzucker
- Herzüberwachung
- Hämatologie
- Koagulation
- Vollblutanalyse
- Überwachung der Vitalfunktionen
- Nicht-invasive Spo2-Überwachung
- Nicht-invasive PCO2-Überwachung
- Bluttransfusion
- Sonstiges
Auf der Grundlage der Anwendung ist der südafrikanische und europäische Markt für Point-of-Care-Tests (POCT) in die Bereiche Blutzucker, Herzüberwachung, Hämatologie, Gerinnung, Vollblutanalyse, Überwachung der Vitalfunktionen, nichtinvasive Spo2-Überwachung, nichtinvasive Pco2-Überwachung, Bluttransfusion und andere unterteilt.
Rezeptmodus
- Verschreibungspflichtige Tests
- Freiverkäufliche Tests
Auf Grundlage der Verschreibungsart ist der südafrikanische und europäische Markt für Point-of-Care-Tests (POCT) in verschreibungspflichtige Tests und rezeptfreie Tests segmentiert.
Plattform
- Lateral-Flow-Assays/Immunchromatographie-Tests
- Ölmessstäbe
- Molekulare Diagnostik
- Immunassays
- Mikrofluidik
- Klinisch-chemischer Test
- Hämatologie
- Sonstiges
Auf der Grundlage der Plattform ist der südafrikanische und europäische Markt für Point-of-Care-Tests (POCT) in Lateral-Flow-Assays/Immunchromatographie-Tests, Teststreifen, Molekulardiagnostik, Immunassays, Mikrofluidik, klinisch-chemische Tests, Hämatologie und andere unterteilt.
Endbenutzer
- Kliniken
- Heimpflege
- Krankenhäuser
- Laboratorien
- Ambulante Chirurgiezentren
- Sonstiges
Auf der Grundlage des Endbenutzers ist der südafrikanische und europäische Markt für Point-of-Care-Tests (POCT) in Kliniken, häusliche Pflege, Krankenhäuser, Labore, ambulante Operationszentren und andere unterteilt.
Vertriebskanal
- Direkte Ausschreibung
- Einzelhandelsumsätze
- Online-Verkäufe
- Sonstiges
Auf der Grundlage der Vertriebskanäle ist der südafrikanische und europäische Markt für Point-of-Care-Tests (POCT) in Direktausschreibungen, Einzelhandelsverkäufe, Online-Verkäufe und Sonstiges unterteilt.
Regionale Analyse/Einblicke zum Point-of-Care-Testing (POCT)-Markt
Der Point-of-Care-Testing-Markt (POCT) wird analysiert und es werden Erkenntnisse und Trends zur Marktgröße nach Land, Produkttyp, Anwendung, Verschreibungsmodus, Plattform, Endbenutzer und Vertriebskanal bereitgestellt.
Die in diesem Bericht abgedeckten Länder sind Südafrika, Deutschland, Frankreich, Großbritannien, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei, Belgien und der Rest von Europa.
Aufgrund des steigenden Bewusstseins und der staatlichen Förderung von POCT-Produkten wird Deutschland voraussichtlich dominieren und im Prognosezeitraum den regionalen Markt ankurbeln.
Die Nachfrage nach Blasenkrebsdiagnostik wird aufgrund des technologischen Fortschritts steigen. Verschiedene Unternehmen ergreifen Initiativen, die schrittweise zum Wachstum des Marktes führen.
Wettbewerbsumfeld und Point-of-Care-Testing (POCT) Marktanteilsanalyse
Die Wettbewerbslandschaft des Point-of-Care-Testing (POCT)-Marktes liefert Einzelheiten zu den Wettbewerbern. Zu den enthaltenen Details gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens auf den Markt.
Zu den wichtigsten Akteuren auf dem Markt zählen unter anderem F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Werfen, Sysmex Europe SE., Danaher, Quidel Corporation, LumiraDx, BD, Abbott, Nova Biomedical, Abaxis, Trividia Health, Inc., Sekisui Diagnostics, Thermo Fisher Scientific Inc., EKF Diagnostics, Trinity Biotech, Chembio Diagnostics, Inc., PTS Diagnostics, binx health, inc. und QuantuMDx Group Ltd.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 STRATEGIC INITIATIVES
5 REGULATORY FRAMEWORK
5.1 REGULATORY SCENARIO IN EUROPE
5.2 REGULATORY SCENARIO IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF INFECTIOUS AND CHRONIC DISEASES
6.1.2 IMPROVED DIAGNOSIS-SEEKING RATE
6.1.3 DEMAND FOR WEARABLE OR PORTABLE GLUCOSE MONITORING DEVICES
6.1.4 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 LACK OF ACCURACY WITH POCT PRODUCTS
6.2.2 HIGH COST OF POCT PRODUCT
6.2.3 LACK OF TRAINING
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 RISING AWARENESS AND GOVERNMENT FUNDING
6.4 CHALLENGES
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
6.4.2 IMPROPER CARE OF POCT DEVICES
7 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 GLUCOSE MONITORING PRODUCTS
7.2.1 STRIPS
7.2.2 METERS
7.2.3 LANCETS AND LANCING DEVICES
7.3 INFECTIOUS DISEASE TESTING PRODUCTS
7.3.1 INFLUENZA TESTING PRODUCTS
7.3.1.1 TRADITIONAL DIAGNOSTIC TEST
7.3.1.1.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)
7.3.1.1.2 DIRECT FLUORESCENT ANTIBODY TEST (DFAT)
7.3.1.1.3 VIRAL CULTURE
7.3.1.1.4 SEROLOGICAL ASSAY
7.3.1.2 MOLECULAR DIAGNOSTIC ASSAY
7.3.1.2.1 RT-PCR
7.3.1.2.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)
7.3.1.2.3 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT)
7.3.1.2.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)
7.3.2 HIV TESTING PRODUCTS
7.3.2.1 TESTING EQUIPMENT
7.3.2.2 TESTING REAGENT
7.3.3 HEPATITIS C TESTING PRODUCTS
7.3.3.1 HCV ANTIBODY TESTS
7.3.3.2 HCV VIRAL LOAD TESTS
7.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING
7.3.4.1 NAAT-BASED SYSTEMS
7.3.4.2 NON–NAAT-BASED SYSTEMS
7.3.5 HEALTHCARE ASSOCIATED INFECTION (HAI) TESTING
7.3.6 RESPIRATORY INFECTION TESTING PRODUCTS
7.3.7 TROPICAL DISEASE TESTING PRODUCTS
7.3.8 COVID 19
7.3.9 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
7.4 CARDIOMETABOLIC MONITORING PRODUCTS
7.4.1 CARDIAC MARKER TESTING PRODUCTS
7.4.1.1 HSTNL
7.4.1.2 BNP
7.4.1.3 D-DIMER
7.4.1.4 CK-MB
7.4.1.5 MYOGLOBIN
7.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
7.4.2.1 CARTRIDGES
7.4.2.2 REAGENTS
7.4.3 HBA1C TESTING PRODUCTS
7.4.3.1 HBA1C TESTING INSTRUMENTS
7.4.3.2 HBA1C TESTING CONSUMABLES
7.4.4 POC ANALYZER
7.4.5 ECG DEVICES
7.4.5.1 RESTING ECG DEVICES
7.4.5.2 STRESS ECG DEVICES
7.4.5.3 HOLTER MONITORS
7.5 PREGNANCY AND FERTILITY TESTING PRODUCTS
7.5.1 PREGNANCY TESTING PRODUCTS
7.5.1.1 STRIPS/ DIP STICKS AND CARDS
7.5.1.2 MID STREAM DEVICES
7.5.1.3 CASSETTES
7.5.1.4 DIGITAL DEVICES
7.5.1.5 LINE-INDICATOR DEVICES
7.5.2 FERTILITY TESTING PRODUCTS
7.5.2.1 HUMAN CHORIONIC GONADOTROPIN (HCG) URINE TEST
7.5.2.2 FSH URINE TEST
7.5.2.3 LUTEINIZING HORMONE (LH) URINE TEST
7.6 HAEMATOLOGY TESTING PRODUCTS
7.7 COAGULATION MONITORING PRODUCTS
7.7.1 ANTICOAGULATION MONITORING DEVICES
7.7.2 PLATELET FUNCTION MONITORING DEVICES
7.7.3 VISCOELASTIC COAGULATION MONITORING DEVICES
7.8 DRUG-OF-ABUSE (DOA) TESTING PRODUCTS
7.8.1 DOA ANALYZERS
7.8.1.1 IMMUNOASSAYS
7.8.1.2 CHROMATOGRAPHIC DEVICES
7.8.1.3 BREATH ANALYZERS
7.8.2 RAPID TESTING DEVICES
7.8.2.1 URINE TESTING DEVICES
7.8.2.2 ORAL FLUID TESTING DEVICES
7.9 URINALYSIS TESTING PRODUCTS
7.9.1 POC URINE STRIP SELF-TESTING
7.9.2 POC URINE TEST STRIP PROFESSIONAL TESTING
7.1 CHOLESTEROL TESTING PRODUCTS
7.10.1 INSTRUMENTS
7.10.1.1 TABLE-TOP ANALYZERS
7.10.1.2 HAND-HELD ANALYZERS
7.10.2 TESTING KITS
7.11 TUMOR/CANCER MARKER TESTING PRODUCTS
7.12 FECAL OCCULT TESTING PRODUCTS
7.12.1 GUAIAC FOB STOOL TEST
7.12.2 IMMUNO-FOB AGGLUTINATION TEST
7.12.3 LATERAL FLOW IMMUNO-FOB TEST
7.12.4 IMMUNO-FOB ELISA TEST
7.13 OTHERS
8 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 BLOOD GLUCOSE
8.3 CARDIAC MONITORING
8.4 HAEMATOLOGY
8.5 COAGULATION
8.6 WHOLE BLOOD ANALYSIS
8.7 VITAL SIGN MONITORING
8.8 NON- INVASIVE SPO2 MONITORING
8.9 NON- INVASIVE PCO2 MONITORING
8.1 BLOOD TRANSFUSION
8.11 OTHERS
9 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE
9.1 OVERVIEW
9.2 PRESCRIPTION-BASED TESTING
9.3 OVER THE COUNTER TESTING
10 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM
10.1 OVERVIEW
10.2 LATERAL FLOW ASSAYS /IMMUNOCHROMATOGRAPHY TESTS
10.3 DIPSTICKS
10.4 MOLECULAR DIAGNOSTICS
10.5 IMMUNOASSAYS
10.6 MICROFLUIDICS
10.7 CLINICAL CHEMISTRY ASSAY
10.8 HEMATOLOGY
10.9 OTHERS
11 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER
11.1 OVERVIEW
11.2 CLINICS
11.3 HOME CARE
11.4 HOSPITALS
11.5 LABORATORIES
11.6 AMBULATORY SURGERY CENTERS
11.7 OTHERS
12 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 ONLINE SALES
12.5 OTHERS
13 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET
13.1 EUROPE
13.1.1 GERMANY
13.1.2 U.K.
13.1.3 FRANCE
13.1.4 SPAIN
13.1.5 ITALY
13.1.6 RUSSIA
13.1.7 NETHERLANDS
13.1.8 SWITZERLAND
13.1.9 TURKEY
13.1.10 BELGIUM
13.1.11 REST OF EUROPE
13.2 SOUTH AFRICA
14 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
14.2 COMPANY SHARE ANALYSIS: SOUTH AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 F HOFFMANN-LA ROCHE LTD
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 SIEMENS HEALTHCARE GMBH
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 WERFEN
16.3.1 1.3.1 COMPANY SNAPSHOT
16.3.2 PRODUCT PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 SYSMEX EUROPE SE.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 DANAHER
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 ABAXIS
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 ABBOTT
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BD
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BINX HEALTH, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 CHEMBIO DIAGNOSTICS SYSTEMS, INC
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 EKF DIAGNOSTICS
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 LUMIRAXDX
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 NOVA BIOMEDICAL
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 PTS DIAGNOSTICS
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 QUANTUMDX GROUP LTD.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 QUIDEL CORPORATION
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 SEKISUI DIAGNOSTICS
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 THERMO FISHER SCIENTIFIC INC.
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENTS
16.19 TRINITY BIOTECH
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENTS
16.2 TRIVIDIA HEALTH, INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 SOUTH AFRICA AND EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 SOUTH AFRICA AND EUROPE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 SOUTH AFRICA AND EUROPE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 SOUTH AFRICA AND EUROPE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 SOUTH AFRICA AND EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 SOUTH AFRICA AND EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 SOUTH AFRICA AND EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 SOUTH AFRICA AND EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 SOUTH AFRICA AND EUROPE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 SOUTH AFRICA AND EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 SOUTH AFRICA AND EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 13 SOUTH AFRICA AND EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 14 SOUTH AFRICA AND EUROPE ECG DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 15 SOUTH AFRICA AND EUROPE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 16 SOUTH AFRICA AND EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 17 SOUTH AFRICA AND EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 18 SOUTH AFRICA AND EUROPE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 19 SOUTH AFRICA AND EUROPE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 20 SOUTH AFRICA AND EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 21 SOUTH AFRICA AND EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 22 SOUTH AFRICA AND EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 23 SOUTH AFRICA AND EUROPE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 24 SOUTH AFRICA AND EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 25 SOUTH AFRICA AND EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 26 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 28 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 29 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 30 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 31 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 32 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 33 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 34 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 35 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 36 EUROPE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 37 EUROPE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 EUROPE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 EUROPE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 40 EUROPE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 41 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 43 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 44 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 46 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 47 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 48 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 49 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 50 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 52 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 53 EUROPE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 56 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 57 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 59 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 60 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 62 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 63 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 65 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 66 EUROPE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 69 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 70 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 72 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 73 EUROPE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 77 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 78 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 80 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 81 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 83 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 84 EUROPE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 87 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 88 EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 90 EUROPE FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 91 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 93 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 94 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 96 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 99 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 100 GERMANY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 GERMANY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 GERMANY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 103 GERMANY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 104 GERMANY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 105 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 107 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 108 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 110 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 111 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 112 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 113 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 114 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 116 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 117 GERMANY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 120 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 121 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 123 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 124 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 126 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 127 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 129 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 130 GERMANY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 131 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 132 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 133 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 134 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 136 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 137 GERMANY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 GERMANY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 141 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 142 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 144 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 145 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 146 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 147 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 148 GERMANY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 149 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 150 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 151 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 152 GERMANY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 GERMANY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 154 GERMANY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 155 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 156 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 157 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 158 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 159 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 160 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 163 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 164 U.K. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 165 U.K. INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 166 U.K. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 167 U.K. TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 168 U.K. TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 169 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 170 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 171 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 172 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 173 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 174 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 175 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 176 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 177 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 178 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 180 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 181 U.K. CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 182 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 183 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 184 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 185 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 186 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 187 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 188 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 189 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 190 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 191 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 192 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 193 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 194 U.K. PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 195 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 196 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 197 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 198 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 199 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 200 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 201 U.K. COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 202 U.K. DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 203 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 204 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 205 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 206 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 207 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 208 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 209 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 210 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 211 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 212 U.K. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 213 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 214 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 215 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 216 U.K. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 217 U.K. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 218 U.K. FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 219 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 220 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 221 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 222 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 223 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 224 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 225 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 226 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 227 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 228 FRANCE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 229 FRANCE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 230 FRANCE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 FRANCE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 232 FRANCE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 233 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 234 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 235 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 236 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 237 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 238 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 239 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 240 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 241 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 242 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 243 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 244 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 245 FRANCE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 246 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 247 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 248 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 249 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 250 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 251 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 252 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 253 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 254 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 255 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 256 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 257 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 258 FRANCE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 259 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 260 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 261 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 262 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 263 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 264 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 265 FRANCE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 266 FRANCE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 267 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 268 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 269 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 270 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 271 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 272 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 273 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 274 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 275 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 276 FRANCE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 277 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 278 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 279 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 280 FRANCE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 281 FRANCE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 282 FRANCE FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 283 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 284 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 285 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 286 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 287 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 288 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 289 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 290 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 291 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 292 SPAIN INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 293 SPAIN INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 294 SPAIN TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 295 SPAIN TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 296 SPAIN TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 297 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 298 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 299 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 300 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 301 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 302 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 303 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 304 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 305 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 306 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 307 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 308 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 309 SPAIN CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 310 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 311 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 312 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 313 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 314 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 315 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 316 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 317 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 318 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 319 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 320 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 321 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 322 SPAIN PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 323 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 324 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 325 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 326 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 327 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 328 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 329 SPAIN COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 330 SPAIN DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 331 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 332 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 333 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 334 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 335 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 336 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 337 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 338 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 339 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 340 SPAIN CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 341 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 342 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 343 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 344 SPAIN FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 345 SPAIN FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 346 SPAIN FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 347 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 348 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 349 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 350 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 351 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 352 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 353 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 354 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 355 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 356 ITALY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 357 ITALY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 358 ITALY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 359 ITALY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 360 ITALY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 361 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 362 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 363 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 364 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 365 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 366 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 367 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 368 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 369 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 370 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 371 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 372 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 373 ITALY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 374 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 375 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 376 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 377 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 378 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 379 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 380 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 381 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 382 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 383 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 384 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 385 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 386 ITALY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 387 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 388 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 389 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 390 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 391 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 392 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 393 ITALY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 394 ITALY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 395 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 396 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 397 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 398 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 399 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 400 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 401 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 402 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 403 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 404 ITALY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 405 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 406 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 407 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 408 ITALY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 409 ITALY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 410 ITALY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 411 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 413 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 414 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 415 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 416 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 417 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 418 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 419 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 420 RUSSIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 421 RUSSIA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 422 RUSSIA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 423 RUSSIA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 424 RUSSIA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 425 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 426 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 427 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 428 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 429 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 430 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 431 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 432 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 433 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 434 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 435 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 436 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 437 RUSSIA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 438 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 439 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 440 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 441 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 442 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 443 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 444 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 445 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 446 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 447 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 448 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 449 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 450 RUSSIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 451 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 452 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 453 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 454 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 455 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 456 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 457 RUSSIA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 458 RUSSIA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 459 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 460 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 461 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 462 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 463 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 464 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 465 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 466 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 467 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 468 RUSSIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 469 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 470 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 471 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 472 RUSSIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 473 RUSSIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 474 RUSSIA FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 475 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 476 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 477 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 478 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 479 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 480 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 481 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 482 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 483 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 484 NETHERLANDS INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 485 NETHERLANDS INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 486 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 487 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 488 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 489 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 490 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 491 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 492 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 493 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 494 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 495 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 496 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 497 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 498 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 499 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 500 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 501 NETHERLANDS CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 502 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 503 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 504 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 505 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 506 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 507 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 508 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 509 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 510 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 511 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 512 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 513 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 514 NETHERLANDS PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 515 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 516 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 517 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 518 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 519 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 520 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 521 NETHERLANDS COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 522 NETHERLANDS DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 523 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 524 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 525 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 526 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 527 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 528 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 529 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 530 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 531 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 532 NETHERLANDS CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 533 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 534 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 535 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 536 NETHERLANDS FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 537 NETHERLANDS FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 538 NETHERLANDS FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 539 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 540 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 541 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 542 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 543 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 544 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 545 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 546 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 547 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 548 SWITZERLAND INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 549 SWITZERLAND INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 550 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 551 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 552 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 553 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 554 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 555 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 556 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 557 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 558 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 559 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 560 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 561 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 562 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 563 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 564 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 565 SWITZERLAND CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 566 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 567 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 568 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 569 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 570 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 571 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 572 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 573 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 574 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 575 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 576 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 577 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 578 SWITZERLAND PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 579 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 580 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 581 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 582 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 583 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 584 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 585 SWITZERLAND COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 586 SWITZERLAND DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 587 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 588 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 589 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 590 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 591 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 592 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 593 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 594 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 595 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 596 SWITZERLAND CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 597 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 598 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 599 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 600 SWITZERLAND FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 601 SWITZERLAND FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 602 SWITZERLAND FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 603 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 604 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 605 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 606 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 607 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 608 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 609 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 610 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 611 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 612 TURKEY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 613 TURKEY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 614 TURKEY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 615 TURKEY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 616 TURKEY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 617 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 618 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 619 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 620 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 621 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 622 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 623 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 624 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 625 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 626 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 627 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 628 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 629 TURKEY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 630 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 631 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 632 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 633 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 634 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 635 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 636 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 637 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 638 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 639 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 640 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 641 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 642 TURKEY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 643 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 644 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 645 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 646 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 647 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 648 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 649 TURKEY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 650 TURKEY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 651 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 652 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 653 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 654 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 655 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 656 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 657 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 658 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 659 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 660 TURKEY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 661 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 662 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 663 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 664 TURKEY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 665 TURKEY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 666 TURKEY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 667 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 668 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 669 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 670 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 671 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 672 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 673 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 674 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 675 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 676 BELGIUM INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 677 BELGIUM INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 678 BELGIUM TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 679 BELGIUM TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 680 BELGIUM TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 681 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 682 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 683 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 684 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 685 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 686 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 687 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 688 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 689 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 690 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 691 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 692 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 693 BELGIUM CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 694 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 695 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 696 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 697 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 698 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 699 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 700 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 701 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 702 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 703 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 704 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 705 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 706 BELGIUM PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 707 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 708 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 709 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 710 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 711 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 712 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 713 BELGIUM COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 714 BELGIUM DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 715 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 716 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 717 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 718 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 719 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 720 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 721 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 722 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 723 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 724 BELGIUM CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 725 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 726 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 727 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 728 BELGIUM FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 729 BELGIUM FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 730 BELGIUM FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 731 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 732 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 733 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 734 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 735 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 736 REST OF EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 737 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 738 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 739 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 740 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 741 SOUTH AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 742 SOUTH AFRICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 743 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 744 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 745 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 746 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 747 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 748 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 749 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 750 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 751 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 752 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 753 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 754 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 755 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 756 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 757 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 758 SOUTH AFRICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 759 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 760 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 761 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 762 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 763 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 764 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 765 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 766 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 767 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 768 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 769 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 770 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 771 SOUTH AFRICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 772 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 773 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 774 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 775 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 776 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 777 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 778 SOUTH AFRICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 779 SOUTH AFRICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 780 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 781 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 782 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 783 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 784 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 785 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 786 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 787 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 788 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 789 SOUTH AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 790 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 791 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 792 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 793 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 794 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 795 SOUTH AFRICA FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 796 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 797 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 798 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)
TABLE 799 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 800 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION
FIGURE 2 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DATA TRIANGULATION
FIGURE 3 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DROC ANALYSIS
FIGURE 4 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC DISEASES AND RISING PATIENT INCLINATION TOWARDS POINT-OF-CARE TESTING ARE EXPECTED TO DRIVE THE GROWTH OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET FROM 2023 TO 2030
FIGURE 12 THE GLUCOSE MONITORING PRODUCTS SEGMENT, IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET
FIGURE 14 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, 2022
FIGURE 19 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 20 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 21 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2022
FIGURE 23 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2023-2030 (USD MILLION)
FIGURE 24 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, CAGR (2023-2030)
FIGURE 25 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE
FIGURE 26 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, 2022
FIGURE 27 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, 2023-2030 (USD MILLION)
FIGURE 28 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, CAGR (2023-2030)
FIGURE 29 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, LIFELINE CURVE
FIGURE 30 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, 2022
FIGURE 31 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SNAPSHOT (2022)
FIGURE 39 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2022)
FIGURE 40 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 43 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY SHARE 2022 (%)
FIGURE 44 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY SHARE 2022 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
